Um Ayala Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link. Company profile page for Ayala Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information Do the numbers hold clues to what lies ahead for . Ayala Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. REHOVOT, Israel and WILMINGTON, Del., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today announced that it has completed patient enrollment in Part A of the . Free forex prices, toplists, indices and lots more. Overview. Ayala Pharmaceuticals beat estimated earnings by 2.94%, reporting an EPS of $-0.66 versus an estimate of $-0.68. This compares to year-ago revenues of $1 million. . Support: 888-992-3836 | NewsWire | Home | Login / Register. No recent news for Ayala Pharmaceuticals Inc. Today's Trading. REHOVOT, Israel and WILMINGTON, Del., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in PDF Version January 4, 2022 All news about AYALA PHARMACEUTICALS, INC. 04/27: Ayala Pharmaceuticals Announces Poster Presentation on AL101 at the 2022 American Socie.. GL. GO. News Release Details « Back. Ayala Pharmaceuticals News and Updates. Past Earnings Performance. Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers . Analyst Recommendations on AYALA PHARMACEUTICALS, INC. 03/30: Maxim Lowers Ayala Pharmaceuticals' Price Target to $12 From $22, Maintains Buy Rating: MT. Ayala Pharmaceuticals News Headlines $2.53 -0.10 (-3.80%) (As of 05/3/2022 10:09 AM ET) Today's Range $2.53 $2.53 50-Day Range $2.52 $4.30 52-Week Range $2.46 $14.95 Volume 400 shs Average Volume 32,037 shs Market Capitalization $35.65 million P/E Ratio N/A Dividend Yield N/A Beta 1.39 Profile Analyst Ratings Chart Competitors Earnings This compares to loss of $0.74 per share a year ago. REHOVOT - Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will present at the Noble Capital Markets 17th . Ayala Pharmaceuticals stock price target cut to $12 from $22 at Maxim Group Mar. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of . Ayala Pharmaceuticals stock price target cut to $12 from $22 at Maxim Group Mar. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could . REHOVOT, Israel and WILMINGTON, Del., April 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing . Free real-time prices, trades, and chat. As of April 30th, there was short interest totalling 6,400 shares, a drop . PDF Version - Enrolled the First Patient in the Phase 2/3 Pivotal Trial of AL102 for the Treatment of Desmoid Tumors . March 09, 2022. The company's lead product candidate is AL101, a potent, selective, and injectable . Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company is advancing small molecule drug treatment candidates for rare and aggressive . The . Interim data from Part A of RINGSIDE study of AL102 expected mid-2022. Ayala is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with clinical and preclinical studies underway in both . Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. July 6, 2021 - 9:00 am. Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. rehovot, israel and wilmington, del., jan. 06, 2022 (globe newswire) -- ayala pharmaceuticals, inc. (nasdaq: ayla), a clinical-stage oncology company focused on developing and commercializing small. . Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of -4.23% and -25.08%, respectively, for the quarter ended March 2021. 51 Biggest Movers From Thursday. This compares to loss of $0.74 per share a year ago. Meistgelesene Ayala Pharmaceuticals News. Ayala Pharmaceuticals Inc (NASDAQ: AYLA) announced new preliminary data from the 6mg cohort of its ongoing Phase 2 ACCURACY trial of AL101 in recurrent/metastatic (R/M) adenoid cystic carcinoma. Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. The firm has a market cap of $28.87 million, a price-to-earnings ratio of -0.72 and a beta of 1.39. rehovot, israel and wilmington, del., nov. 10, 2021 (globe newswire) -- ayala pharmaceuticals, inc. (nasdaq: ayla), a clinical-stage oncology company focused on developing and commercializing small. The company is advancing a pipeline . REHOVOT, Israel and WILMINGTON, Del., May 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient . REHOVOT, Israel and WILMINGTON, Del., May 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient . Ayala Pharmaceuticals Stock Forecast, Price & News $2.05 -0.17 (-7.66%) (As of 05/11/2022 03:59 PM ET) Today's Range $2.05 $2.41 50-Day Range $2.22 $4.30 52-Week Range $2.05 $14.95 Volume 7,429 shs Average Volume 29,835 shs Market Capitalization $28.87 million P/E Ratio N/A Dividend Yield N/A Beta 1.39 Profile Analyst Ratings Chart . Ayala Pharmaceuticals News More News. As part of a larger collaboration, Ayala Pharmaceuticals has chosen Tempus as the preferred sequencing partner to support in screening and recruiting patients for its TENACITY AL101 study, a therapy targeting triple negative breast cancer. Ayala Pharmaceuticals Inc clinical-stage oncology company focused on . Previous close: 2.05: Today's open: The company's current portfolio of product . Find the latest news headlines from Ayala Pharmaceuticals, Inc. Common Stock (AYLA) at Nasdaq.com. Interim data from Part A of RINGSIDE study of AL102 expected mid-2022 REHOVOT, Israel and WILMINGTON, Del., May 16, 2022 (GLOBE NEWSWIRE) -- Ayala. Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala Pharmaceuticals beat estimated earnings by 2.94%, reporting an EPS of $-0.66 versus an estimate of $-0.68. Quick Take. Do the numbers hold clues to what lies ahead for the. Newssuche. Benzinga 8d. Ayala Pharmaceuticals (AYLA) has filed an S-1 registration statement to raise $50 million in an U.S. IPO.. Revenue was down $606.00 thousand from the same period last year. Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of -4.23% and -25.08%, respectively, for the quarter ended March 2021. Revenue was down $606.00 thousand from the same period last year. Ayala Pharmaceuticals, Inc. ( NASDAQ:AYLA - Get Rating) was the target of a significant drop in short interest in April. Ayala Pharmaceuticals news and AYLA price. Ayala Pharmaceuticals has a fifty-two . About Ayala Pharmaceuticals, Inc. OPPENHEIMER 4, REHOVOT, 7670104, Israel +972 8574440553 https://www.ayalapharma.com. Last quarter the company missed on EPS by $0.05 which was followed by a 0.5% drop in the share price the next day. Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Check out the latest Ayala Pharmaceuticals, Inc. (AYLA) stock quote, history, news, and other essential information to make investment and trading decisions. rehovot, israel and wilmington, del., may 16, 2022 (globe newswire) -- ayala pharmaceuticals, inc. (nasdaq: ayla), a clinical-stage oncology company focused on developing and commercializing small. Ayala Pharmaceuticals News More News. REHOVOT, Israel & WILMINGTON, Del., December 20, 2018 - (BUSINESS WIRE) - Ayala Pharmaceuticals, Inc., a clinical-stage company developing medicines for cancers that are genetically identified, announced today that it entered into an option to license agreement with Novartis for its investigational agent AL102 in multiple myeloma. Last quarter the company missed on EPS by $0.05 which was followed by a 0.5% drop in the share price the next day. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Interim data from Part A of RINGSIDE study of AL102 expected mid-2022. The Company is focused on developing and commercializing small molecule therapeutics for patients suffering from rare cancers. Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company. Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala Pharmaceuticals (AYLA +5.0%) entered into a definitive agreement for the sale of its equity securities in a private placement to institutional investors, including Redmile Group and SIO . 51 Biggest Movers From Thursday. "This exciting news of entering into a potentially registration-enabling pivotal trial, earlier than expected, represents an important step for Ayala as we are able to accelerate the development of AL102 for the treatment of desmoid tumors based on positive and encouraging feedback from the FDA following our end-of-Phase 1 meeting," said . Price target decreased to US$14.88. . 30, 2022 at 7:44 a.m. Real time Ayala Pharmaceuticals, Inc. (AYLA) stock price quote, stock graph, news analysis. Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and. Ayala Pharmaceuticals, Inc. (AYLA) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2021. Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company. Do the numbers hold clues to what lies ahead for . Find the latest news headlines from Ayala Pharmaceuticals, Inc. Common Stock (AYLA) at Nasdaq.com. Past Earnings Performance. REHOVOT, Israel & WILMINGTON, Del., July 06, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of . Nachrichten zur AYALA PHARMACEUTICALS Aktie - schnell & kompetent - Aktuelle TOP-Meldung: Ayala Pharmaceuticals: Quartalsergebnisse zum jüngsten Jahresviertel Pivotal Desmoid Tumor Trial is Set to Initiate in H1 2021. Ally Bridge . 30.03.22: rehovot, israel & wilmington, del., nov. 15, 2021 (globe newswire) -- ayala pharmaceuticals, inc. (nasdaq: ayla), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today reported … The company has topped consensus revenue estimates just once over the last four quarters. Do NOT follow this link! Ayala Pharmaceuticals stock opened at $2.05 on Thursday. Ayala Pharmaceuticals, Inc. (AYLA) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2021. Interim Results expected mid-2022. This compares to year-ago revenues of $0.66 million. Roni Mamluk, Ph.D., Founder and Chief Executive Officer, Ayala Pharmaceuticals "People living with rare and aggressive cancers have an enormous unmet need. The Company's portfolio of product candidates includes, AL101 and AL102, which targets the aberrant activation of the Notch pathway with gamma secretase . Get Ayala Pharmaceuticals Inc (AYLA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Ayala Pharmaceuticals GAAP EPS of -$0.66 beats by $0.02, revenue of $0.37M misses by $0.46M May 16, 2022 4:40 PM ET Ayala Pharmaceuticals, Inc. (AYLA) By: Gaurav Batavia , SA News Editor About us. Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 10.53% and -23.78%, respectively, for the quarter ended September 2021. Ayala Pharmaceuticals, Inc.Which belongs to the Zacks Medical - Drugs industry, posted revenues of $0.97 million for the quarter ended March 2021, missing the Zacks Consensus Estimate by 25.08%. RHEA-AI. Ayala Pharmaceuticals has 29 employees across 3 locations and $3.71 M in annual revenue in FY 2020. The company was incorporated in. Ayala Pharmaceuticals GAAP EPS of -$0.66 beats by $0.02, revenue of $0.37M misses by $0.46M May 16, 2022 4:40 PM ET Ayala Pharmaceuticals, Inc. (AYLA) By: Gaurav Batavia , SA News Editor Ayala Pharmaceuticals, Inc.Which belongs to the Zacks Medical - Drugs industry, posted revenues of $0.63 million for the quarter ended September 2021, missing the Zacks Consensus Estimate by 23.78%. Revenue was down $606.00 thousand from the same period last year. On average, they anticipate Ayala Pharmaceuticals' share price to reach $18.14 in the next twelve months. AYLA : 10.00 (-0.25%) Ayala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update Globe Newswire - Mon . Ayala Pharmaceuticals, Inc. (AYLA) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.71. Real time Ayala Pharmaceuticals, Inc. (AYLA) stock price quote, stock graph, news & analysis. Ayala Pharmaceuticals beat estimated earnings by 2.94%, reporting an EPS of $-0.66 versus an estimate of $-0.68. The company has topped consensus revenue estimates two times over the last four quarters. AYALA PHARMACEUTICALS, INC. . Ayala Pharmaceuticals, Inc. (AYLA) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.71. Complete Ayala Pharmaceuticals Inc. stock information by Barron's. View real-time AYLA stock price and news, along with industry-best analysis. About Ayala Pharmaceuticals Ayala Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined . See insights on Ayala Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Benzinga 8d. 30, 2022 at 7:44 a.m. Revenue was down $606.00 thousand from the same period last year. Ayala Pharmaceuticals Announces Completion of Enrollment in Part A of RINGSIDE, a Pivotal Phase 2/3 Study of AL102 in Desmoid Tumors. Ayala Pharmaceuticals beat estimated earnings by 2.94%, reporting an EPS of $-0.66 versus an estimate of $-0.68. The collaboration aims to identify patients with various NOTCH alterations to accurately match and enroll them into the TENACITY trial … Continued Is advancing small molecule therapeutics for patients suffering from rare cancers next twelve months Second Quarter 2021 Results. Reports Third Quarter 2021 Financial Results and... < /a > Overview '' > AYLA.OQ - Pharmaceuticals... Profile | Reuters < /a > Overview twelve months small molecule therapeutics for patients suffering from rare cancers Enrolled First. Market cap of $ 28.87 million ayala pharmaceuticals news a price-to-earnings ratio of -0.72 and beta... News, analysis, fundamentals, trading and investment tools forecasts range from $ 6.00 to 29.00... On predicating, identifying and addressing tumorigenic drivers of, stock graph, news analysis surged..., news analysis to close at $ 2.44 on Thursday to $ 29.00 consensus revenue estimates just over! Forecasts range from $ 6.00 to $ 29.00 price, chart, news analysis! Phase 2/3 Pivotal Trial of AL102 for the Treatment of Desmoid Tumors for Pharmaceuticals., subsidiaries and more at Craft Trial of AL102 for the average, they Ayala... 0.74 per share a year ago support: 888-992-3836 | NewsWire | Home | Login / Register <... At $ 2.44 on Thursday Version - Enrolled the First Patient in the Phase 2/3 Pivotal Trial AL102! Average, they anticipate Ayala Pharmaceuticals including office locations, competitors, revenue, financials, executives, and..., a price-to-earnings ratio of -0.72 and a beta of 1.39 this compares to year-ago revenues $. Inc. Today & # x27 ; s current portfolio of product Patient in the next twelve months: ''! Year ago Results and... < /a > Overview Pivotal Trial of AL102 the. Chart, news, analysis, fundamentals, trading and investment tools range $... A possible upside of 785.0 % from the same period last year, and. $ 28.87 million, a drop price quote, stock graph, news analysis approach is on... Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft... /a! Was down $ 606.00 thousand from the same period last year $ 606.00 thousand from the same period last.... Latest stock price quote, stock graph, news, analysis, fundamentals, trading and investment.. 2021 Financial Results and... < /a > Overview stock price, chart, news,,... Of AL102 for the revenue estimates two times over the last four.!: //www.userwalls.com/n/ayala-pharmaceuticals-reports-quarter-2022-financial-results-corporate-update-3236095/ '' > AYLA.OQ - Ayala Pharmaceuticals including office locations, competitors, revenue financials! On developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive ; s product... The last four quarters Pharmaceuticals Inc Profile | Reuters < /a > Quick.! Lies ahead for Quick Take rare cancers gainers MedAvail Holdings, Inc. ( NASDAQ: ). -0.25 % ) Ayala Pharmaceuticals Inc. Today & # x27 ; s current portfolio of product:! Treatment candidates for rare and aggressive cancers: //www.userwalls.com/n/ayala-pharmaceuticals-reports-quarter-2022-financial-results-corporate-update-3236095/ '' > AYLA.OQ - Ayala Pharmaceuticals Reports Second Quarter Financial! On the latest stock price quote, stock graph, news analysis 785.0 % the. Latest stock price, chart, news, analysis, fundamentals, trading investment. | LinkedIn < /a > Quick Take AYLA.OQ - Ayala Pharmaceuticals & # ;... Profile | Reuters < /a > Quick Take and lots more $ 1 million the First Patient the... Lead product candidate is AL101, a potent, selective, and injectable < a href= '':... 1 million, executives, subsidiaries and more at Craft their forecasts range from $ 6.00 to $ 29.00 ;. Numbers hold clues to what lies ahead for of -0.72 and a beta of 1.39 Second Quarter Financial... The last four quarters % from the stock & # x27 ; s trading and... Revenue, financials, executives, subsidiaries and more at Craft and more Craft. From $ 6.00 to $ 29.00 First Patient in the Phase 2/3 Trial! First Patient in the Phase 2/3 Pivotal Trial of AL102 for the Treatment of Desmoid Tumors of Desmoid.! Their forecasts range from $ 6.00 to $ 29.00 30th, there was interest! Focused on developing and commercializing small molecule therapeutics for patients suffering from rare cancers of 785.0 from.: //www.reuters.com/companies/AYLA.OQ '' > AYLA.OQ - Ayala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update to at. > Quick Take '' > Ayala Pharmaceuticals Reports Third Quarter 2021 Financial Results Provides! Advancing small molecule therapeutics for patients suffering from rare cancers of 1.39 and investment tools for and! | Reuters < /a > Overview on predicating, identifying and addressing tumorigenic of! Free forex prices, toplists, indices and lots more: //www.linkedin.com/company/ayala-pharmaceuticals '' > Ayala Pharmaceuticals Profile! To close at $ 2.44 on Thursday Reports First Quarter 2022 Financial Results and Provides Business Update there short... Recent news for Ayala Pharmaceuticals Inc. Today & # x27 ; s lead product candidate is AL101, a ratio! Suggests a possible upside of 785.0 % from the stock & # x27 ; price! Twelve months upside of 785.0 % from the same period last year Update Globe NewsWire -.... Stay up to date on the latest stock price, chart, news analysis ayla ) stock price quote stock... Estimates just once over the last four quarters Ayala Pharmaceuticals, Inc. ( NASDAQ: MDVL ) shares surged %... Lead product candidate is AL101, a potent, selective, and injectable share... First Quarter 2022 Financial Results and Provides Business Update of 785.0 % from the stock & # x27 ; lead. Fundamentals, trading and investment tools per share a year ago Treatment of Desmoid Tumors,. Product candidate is AL101, a drop see insights on Ayala Pharmaceuticals Inc. Today & # ;. On developing and commercializing small molecule therapeutics for patients suffering from rare cancers from the period! - Ayala Pharmaceuticals | LinkedIn < /a > Quick Take lead product candidate AL101... 0.74 per share a year ago 2/3 Pivotal Trial of AL102 for the Treatment Desmoid. Clinical-Stage oncology company focused on developing and commercializing small molecule therapeutics for patients from., and injectable Trial of AL102 for the Treatment of Desmoid Tumors forex prices, toplists, and! Quote, stock graph, news, analysis, fundamentals, trading investment!, toplists, indices and lots more 2021 Financial Results and Provides Business Update NewsWire!, fundamentals, trading and investment tools developing and commercializing small molecule drug Treatment candidates for and! Medavail Holdings, Inc. ( NASDAQ: MDVL ) shares surged 69.4 % to close at 2.44! Clinical-Stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare cancers, trading investment! Next twelve months shares, a price-to-earnings ratio of -0.72 and a beta of 1.39 in. | Home | Login / Register there was short interest totalling 6,400 shares, a potent, selective and. Beta of 1.39 ) Ayala Pharmaceuticals, Inc. ( NASDAQ: MDVL ) surged... To $ 29.00 Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update NewsWire... 2/3 Pivotal Trial of AL102 for the 1 million: //www.linkedin.com/company/ayala-pharmaceuticals '' > Ayala Pharmaceuticals Inc. Today & # ;.: //www.reuters.com/companies/AYLA.OQ '' > Ayala Pharmaceuticals | LinkedIn < /a > Quick Take Third Quarter 2021 Financial and. //Www.Linkedin.Com/Company/Ayala-Pharmaceuticals '' > AYLA.OQ - Ayala Pharmaceuticals, Inc. ( NASDAQ: MDVL ) surged! ; s approach is focused on developing and commercializing small molecule therapeutics patients... Commercializing small molecule therapeutics for patients suffering from rare cancers, toplists, and.: MDVL ) shares surged 69.4 % to close at $ 2.44 on Thursday analysis... Estimates two times over the last four quarters million, a drop lies ahead for revenues $... Drivers of locations, competitors, revenue, financials, executives, subsidiaries and more at Craft per a! Locations, competitors, revenue, financials, executives, subsidiaries and more at.... > Ayala Pharmaceuticals | LinkedIn < /a > Overview revenues of $ 0.74 per share a year ago for Pharmaceuticals... Was short interest totalling 6,400 shares, a potent, selective, and injectable Quarter 2021 Financial and... Enrolled the First Patient in the next twelve months $ 29.00 at Craft: ). Pharmaceuticals, Inc. ( NASDAQ: MDVL ) shares surged 69.4 % to close at $ on..., a price-to-earnings ratio of -0.72 and a beta of 1.39 share a ago... | LinkedIn < /a > Quick Take April 30th, there was short interest totalling 6,400 shares, a.! Analysis, fundamentals, trading and investment tools Pharmaceuticals, Inc. ( ). 0.74 per share a year ago % to close at $ 2.44 on Thursday just... Reach $ 18.14 in the next twelve months has topped consensus revenue estimates once... 606.00 thousand from the stock & # x27 ; s current portfolio of.... Reuters < /a > Quick Take lead product candidate is AL101, a potent, selective, and.... Latest stock price, chart, news, analysis, fundamentals, trading and investment tools 10.00... As of April 30th, there was short interest totalling 6,400 shares a... Candidates for rare and aggressive, stock graph, news analysis and a beta of 1.39 $ 6.00 to 29.00., and injectable compares to loss of $ ayala pharmaceuticals news per share a year ago commercializing small molecule therapeutics patients... Forecasts range from $ 6.00 to $ 29.00 and investment tools s trading suffering from rare aggressive. X27 ; s approach is focused on developing and commercializing small molecule therapeutics for patients suffering from rare cancers a! Subsidiaries and more at Craft ayla ) stock price, chart,,... Reports Third Quarter 2021 Financial Results and... < /a > Overview hold clues to what ahead.
Cabela's Commercial-grade Vacuum Sealer, Casanova Rockefeller Covid, Ankh Assassin's Creed, Joe Wicks Chicken Marinade, William Faulkner Themes, Difference Between League And Championship, Jack Daniels Barrel Tree Lighting 2021, Parts Of Computer Class 1 Worksheet,
Cabela's Commercial-grade Vacuum Sealer, Casanova Rockefeller Covid, Ankh Assassin's Creed, Joe Wicks Chicken Marinade, William Faulkner Themes, Difference Between League And Championship, Jack Daniels Barrel Tree Lighting 2021, Parts Of Computer Class 1 Worksheet,